These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 30877769)

  • 1. Molecular classification of IDH-mutant glioblastomas based on gene expression profiles.
    Wu F; Chai RC; Wang Z; Liu YQ; Zhao Z; Li GZ; Jiang HY
    Carcinogenesis; 2019 Jul; 40(7):853-860. PubMed ID: 30877769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma.
    Hu X; Martinez-Ledesma E; Zheng S; Kim H; Barthel F; Jiang T; Hess KR; Verhaak RGW
    Neuro Oncol; 2017 Jun; 19(6):786-795. PubMed ID: 28340142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
    Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
    J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a Good-Prognosis IDH-Mutant-Like Population of Patients with Diffuse Gliomas.
    Wang Z; Liu X; Wang Z; Bao Z; Zhang W; Zhang C; Jiang T
    Curr Mol Med; 2018 Mar; 17(7):518-526. PubMed ID: 29437008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
    Paul Y; Mondal B; Patil V; Somasundaram K
    Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
    Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
    Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
    Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
    Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses.
    Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A
    Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
    Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
    J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas.
    Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
    Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
    J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A five-microRNA signature for individualized prognosis evaluation and radiotherapy guidance in patients with diffuse lower-grade glioma.
    Zhang JH; Hou R; Pan Y; Gao Y; Yang Y; Tian W; Zhu YB
    J Cell Mol Med; 2020 Jul; 24(13):7504-7514. PubMed ID: 32412186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic screening identifies GABRD, a subunit gene of GABAA receptor as a prognostic marker in adult IDH wild-type diffuse low-grade glioma.
    Zhang H; Zhang L; Tang Y; Wang C; Chen Y; Shu J; Zhang K
    Biomed Pharmacother; 2019 Oct; 118():109215. PubMed ID: 31545245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma.
    Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ
    J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic-related gene pairs signature analysis identifies ABCA1 expression levels on tumor-associated macrophages as a prognostic biomarker in primary IDH
    Wang S; Li L; Zuo S; Kong L; Wei J; Dong J
    Front Immunol; 2022; 13():869061. PubMed ID: 36248907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
    Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
    Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX1 and REXO2 are associated with the heterogeneity and prognosis of IDH wild type lower grade glioma.
    Wang H; Wang X; Xu L; Zhang J; Cao H
    Sci Rep; 2021 Jun; 11(1):11836. PubMed ID: 34088969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.